Affinivax Revenue and Competitors

Boston, MA USA

Location

$377.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Affinivax's estimated annual revenue is currently $5.2M per year.(i)
  • Affinivax's estimated revenue per employee is $77,500
  • Affinivax's total funding is $377.5M.

Employee Data

  • Affinivax has 67 Employees.(i)
  • Affinivax grew their employee count by -68% last year.

Affinivax's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is Affinivax?

Affinivax is a clinical stage biotechnology company developing a next generation approach in vaccine technologies to design both preventive and therapeutic vaccines that provide broader protection against infectious and other immune mediated diseases.

keywords:N/A

$377.5M

Total Funding

67

Number of Employees

$5.2M

Revenue (est)

-68%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Affinivax News

2022-03-22 - Affinivax Reacquires Rights from Astellas for ASP3772, a ...

Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and...

2022-03-22 - Affinivax reacquires rights from Astellas for ASP3772

Following the closing of the transaction with Astellas, ASP3772 would become the most advanced vaccine candidate in Affinivax's pipeline, along...

2021-01-08 - Affinivax Raises $226M in Series C Financing

Affinivax, Inc., a Cambridge, MA-based clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, closed a $226m Series C financing. The round was co-led by new investors Rock Springs Capital and ...

2021-01-08 - Buoyed by renewed clamor for infectious disease R&D, Affinivax nabs huge $226M funding round

After getting off a meaty $120 million round in April, the height of the first wave of COVID-19 infections in the West, Affinivax is a clear indicator that infectious disease and vaccine work is here to stay. Sponsored by Agilent Technologies How would you like to win free bench space at Lab C ...

2021-01-08 - T. Rowe Price Joins $226 Million Series C for Affinivax

Affinivax, Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS platform, today announced the closing of a $226 million Series C financing, co-led by new investors Rock Springs Capital and Foresite Capital. Additional new investor ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.3M675%N/A
#2
$8.5M67-12%$55.9M
#3
$17.5M676%N/A
#4
$10.4M6749%N/A
#5
$9M6722%N/A